Article info
PDFStudent essay
Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
- Correspondence to Landon James Rohowetz, University of Missouri - Kansas City School of Medicine, Kansas City, MO 64108, USA; ljrvx8{at}mail.umkc.edu
Citation
Off-label use of bevacizumab in the treatment of retinal disease: ethical implications
Publication history
- Received December 1, 2018
- Revised June 23, 2019
- Accepted June 28, 2019
- First published July 18, 2019.
Online issue publication
October 15, 2019
Article Versions
- Previous version (15 October 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
- Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
- Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
- Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
- Why using Avastin for eye disease is so difficult
- Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
- Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
- Implications of “not me” drugs for health systems: lessons from age related macular degeneration
- Why have UK doctors been deterred from prescribing Avastin?